Regenxbio (NASDAQ: RGNX) announces its next round
of earnings Tuesday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.
Earnings and Revenue
Regenxbio's per-share loss will be near 82 cents per share on sales of $810,000, according to Wall Street analysts.
Regenxbio's loss in the same period a year ago was 74 cents per share. Quarterly sales came in at $1.69 million. The Wall Street
consensus estimate for earnings would represent a 10.81 percent decrease for the company. Revenue would be down 52.24 percent on a
year-over-year basis.
Here's how the company's reported EPS has compared to analyst estimates in the past:
| Quarter |
Q3 2017 |
Q2 2017 |
Q1 2017 |
Q4 2016 |
| EPS Estimate |
-0.72 |
-0.75 |
-0.76 |
-0.75 |
| EPS Actual |
-0.67 |
-0.47 |
-0.82 |
-0.74 |
Stock Performance
Over the last 52-week period, shares are up 49.24 percent. Given that these returns are generally positive, long-term
shareholders are probably content going into this earnings release. Analysts have adjusted their estimates lower for EPS and
revenues over the past 90 days. The popular rating by analysts on Regenxbio stock is a Neutral. The strength of this rating has
risen over the past 90 days.
Conference Call
Regenxbio's conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.